Estradiol Patch
Product Images NDC 50090-7985

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Estradiol (NDC 50090-7985). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Estradiol Structural Formula (Image 01)

Chemical structure of estradiol showing its steroid backbone and functional groups, including hydroxyl groups and a methyl group, with a hemi-hydrate component indicated.*

FDA Label Image

Transdermal Parts (Image 02)

An illustration diagram of a transdermal patch for Estradiol showing its layers labeled as foam backing with adhesive layer, polyester film, acrylate adhesive matrix containing estradiol, and protective liner.*

FDA Label Image

Figure 1 Mean Serum 17β-estradiol Concentrations Vs. Time Profile Following Application Of A 7.75 Cm2 Transdermal Patch And Application Of A 15.5 Cm2 Estradiol Transdermal System Continuous Delivery (once-weekly) Patch (Image 03)

A line graph showing estradiol concentration (pg/mL) over time (hours) for two estradiol transdermal systems of different sizes (7.75 cm² and 15.5 cm²). Concentrations rise after application, peak between 20 and 40 hours, and decline gradually until 180 hours.*

FDA Label Image

Figure 2 Observed Mean (± S.e.) Estradiol Serum Concentrations For A One Week Application Of The Estradiol Transdermal System Continuous Delivery (once-weekly) (31 Cm2) To The Abdomen And Buttocks Of 38 Postmenopausal Women (Image 04)

A line graph depicting the mean concentration (pg/mL) of estradiol over time in hours after patch application, comparing two treatment sites: buttock and abdomen. The x-axis represents sampling time up to 192 hours, and the y-axis shows the mean concentration levels, with error bars indicating variability.*

FDA Label Image

Figure 3 Mean Percent Change From Baseline In Lumbar Spine (a-p View) Bone Mineral Density By Treatment And Time Last Observation Carried Forward (Image 05)

A line graph depicting percentage change over time from baseline to 24 months in response to treatment with different sizes of Estradiol transdermal patches (7.75 cm², 15.5 cm², 18.6 cm², and 31 cm²) compared to placebo. The x-axis represents treatment visits at baseline, 6, 12, 18, and 24 months, while the y-axis shows percent change values, evidencing positive changes with Estradiol patches and negative change with placebo over time.*

FDA Label Image

Figure 4 Mean Percent Change From Baseline In Total Hip By Treatment And Time Last Observation Carried Forward (Image 06)

A line graph depicting percent change over time from baseline at visits 6 months, 12 months, 18 months, and 24 months. It compares treatment effects of placebo and three different patch sizes (7.75 cm², 15.5 cm², 18.6 cm², and 31 cm²). Each treatment is represented by a distinct line style. The graph shows trends in percent change for each group across visits.*

FDA Label Image

Instructions For Use Figure A (Image 07)

Estradiol Transdermal System, USP Continuous Delivery (Once-Weekly) patch packaging. The image shows a single-pack unit labeled as containing 1 system. It is produced by Mylan. The product is a transdermal patch for delivering estradiol.*

FDA Label Image

Instructions For Use Figures B And C (Image 08)

Illustrations showing how to open and remove the Estradiol transdermal patch (Once-Weekly). Figure B highlights tear notches on the patch packaging. Figure C demonstrates carefully removing the patch from the packaging. The patch label shows 'Estradiol Transdermal System, USP Continuous Delivery (Once-Weekly)' with manufacturer Mylan.*

FDA Label Image

Instructions For Use Figures D And E (Image 09)

Illustrations showing a step in applying an Estradiol transdermal patch. One image zooms in on the patch and its protective liner, and another shows hands peeling off the protective liner from the circular Estradiol patch.*

FDA Label Image

Instructions For Use Figures F And G (Image 10)

Illustrations showing correct application sites for the estradiol transdermal patch on the lower abdomen (Figure F) and on the buttocks (Figure G). Each figure depicts a hand pressing a round patch onto the skin at the specified body location.*

FDA Label Image

Instructions For Use Figure H (Image 11)

An instructional illustration labeled 'Figure H' showing the application of an Estradiol 0.025 mg/day transdermal patch to the skin near the wrist area on a hand. The image depicts the correct placement for the patch.*

FDA Label Image

Label Image (Lbl500907985)

Estradiol 0.025 mg/d transdermal patch by A-S Medication Solutions. The label displays the product name, strength, dosage form, and route, indicating it is a once-weekly system with 4 transdermal systems per package. Storage instructions advise keeping the product at 65 to 77 degrees Fahrenheit and not to store unpunched patches.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.